mTORC2 Inhibition Improves Morphological Effects of PTEN Loss, But Does Not Correct Synaptic Dysfunction or Prevent Seizures

Article Information

DOI

PubMed

Published By

History

¹Department of Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington, Vermont 05405
²Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire 03755
³Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, Virginia 24016
⁴School of Neuroscience, Virginia Polytechnic and State University, Blacksburg, Virginia 24061

Author contributions: E.R.C., K.T., A.N.S., B.W.L., and M.C.W. designed research; E.R.C., K.T., A.N.S., B.W.L., and M.C.W. performed research; E.R.C., K.T., B.W.L., and M.C.W. analyzed data; E.R.C. wrote the first draft of the paper; E.R.C., K.T., B.W.L., and M.C.W. wrote the paper; A.N.S. and M.C.W. edited the paper.

This work was supported by Autism Speaks Predoctoral Grant 11857 to K.T.; National Institutes of Health Grant R01 MH097949 to B.W.L and Grant R01 NS110945 to M.C.W.; and COBRE Grant P20GM135007 to the Customized Physiology and Imaging Core at UVM.
The authors declare no competing financial interests.
Correspondence should be addressed to Bryan W. Luikart at bryan.w.luikart{at}dartmouth.edu or Matthew C. Weston at matthew.c.weston{at}med.uvm.edu

HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
MH097949; NS110945
Autism Speaks (AS)
11857

Select a custom date range for the past year